Peter Olagunju


Peter Olagunju MBA is the Senior Director of Patient Operations with Bluebird Bio Inc. In this role, he is responsible for managing the Centers of Excellence (COE) interfaces in supporting the collection of patient cells, manufacture of drug product, and operational execution of treatments. Prior to Bluebird Bio Inc., Peter Olagunju most recently served as Senior Director, Global Technical Operations at Valeant Pharmaceuticals (through the acquisition of Dendreon Corp.).  He was at Dendreon Corp. for roughly 5 years where he managed the US and EU manufacturing operations and supply chain, including contract manufacturers, external testing sites, and the apheresis network for those regions. Prior to Dendreon Corp., Peter Olagunju had leadership positions within the quality function at a monoclonal antibody organization (ZymoGenetics) that was acquired by BMS in 2011. Peter did his undergraduate studies at the University of Illinois and completed an MBA program at the Foster School of Business (University of Washington).